

Sawada
cont.
R

--18. (New) The system for averting undesirable drug interaction of claim 3, wherein said drug and the concomitant drug are both metabolized by the same molecular species of drug-metabolizing enzyme in humans.

19. (New) The system for averting undesirable drug interaction of claim 3, wherein the concomitant drug is metabolized by the molecular species of the drug-metabolizing enzymes that is inhibited by the said drug.

20. (New) The system for averting undesirable drug interaction of claim 18, wherein said drug and the concomitant drug are both metabolized by CYP3A4.

21. (New) The system for averting undesirable drug interaction of claim 19, the concomitant drug is metabolized by CYP3A4 and said drug inhibits CYP3A4.--

REMARKS

After entry of this amendment, claims 3-4, 7-9, 12-14 and 16-21 are pending in this application and are presented for examination. Claims 1, 2, 5, 6, 10, 11 and 15 have been canceled without prejudice. Claims 18-21 are newly added. No new matter has been introduced with the foregoing amendments and newly added claims.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made." In addition, for the Examiner's convenience, the pending claims are set forth in the Appendix. Reconsideration is respectfully requested.

I. SUPPORT FOR NEW CLAIMS

Support for new claims 18-21 is found throughout the application as filed. More particularly, support for new claims 18-21 is found for example, on page 6, lines 7-12. As such, no new matter has been introduced. Thus, Applicants respectfully request that the new claims be entered.